Antiverse raises £3.5M ($4.6M) to advance generative AI antibody design platform

• Increases total equity financing raised to £7.2M ($10.1M)
• New facilities in Boston and Prague will provide increased capacity to deliver pipeline of pharma and biotech projects
• Funding to progress internal assets targeting multiple GPCRs and Ion Channels towards clinical trials

Cardiff, Wales, UK, 15 October 2024: Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many in partnership with pharmaceutical companies. The latest investment round was led by i&i Biotech Fund I (i&i Bio) and Kadmos Capital, with additional investment from existing investors InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub. This brings the total equity financing raised to £7.2M ($10.1M).

The funding will be used to expand the Company’s laboratory and machine learning teams, bolstering the development of its internal assets against G-protein-coupled receptors (GPCRs) and ion channels towards the clinic, as well as facilitating ongoing collaborations with pharma and biotech companies. The funding will also be used to improve the predictive accuracy of the design platform, focusing on curating training data. Lastly, Antiverse has opened new facilities in Boston, MA, and Prague, Czech Republic, demonstrating its expansion.

Antiverse uses a machine-learning-centred approach to design antibodies for challenging targets, helping to bring needed therapies to patients. The current version of the platform uses ‘target-specific libraries’. These libraries are designed by using structural and sequence data to generate a library with high confidence against the target. This enhances the predictive accuracy compared to traditional antibody libraries, enabling Antiverse to design antibodies for many challenging targets, including GPCRs and ion channels. The platform accelerates the antibody discovery process to 6 months.

 Murat Tunaboylu, Co-Founder and CEO of Antiverse said: “A third of all FDA-approved drugs target GPCRs, yet, despite decades of research and billions of funding, only a few GPCR-targeting antibodies exist. Thanks to the support of our investors, we are one step closer to making GPCRs and other challenging targets druggable, bringing needed therapies to patients across the globe.”

Jaromir Zahradka, CEO at i&i Bio, commented: “Antiverse has made significant progress in the field of antibody design. Antiverse’s mission to make GPCRs druggable focuses on a key issue and we are pleased to be supporting them.”

John Gebeily, Operating Partner at Kadmos Capital, added: “Antiverse’s AI-driven antibody design platform demonstrates significant potential in advancing the development of novel antibody therapeutics, particularly for complex drug targets. We’re excited to support Murat and the team in their effort to significantly accelerate the development of life-saving treatments, and have a transformative impact on the pharmaceutical industry.”